Aim To estimate the plasma acylation-stimulating protein (ASP) level in coronary heart disease patients, and to investigate the correlation of plasma ASP with blood lipids. Methods 109 subjects were involved in this study, including 62 coronary heart disease patients and 47 health controls. Enzyme linked immunosorbent assay (ELISA) technique was used to determine the plasma ASP concentration. Blood lipid levels were detected by immune turbidimetry. Results The levels of plasma ASP were increased significantly in coronary heart disease group compared with control group (P< 0.05). Body mass index (BMI), systolic blood pressure, diastolic blood pressure, total cholesterol (TC), triglyceride, low density lipoprotein (LDL) and apolipoprotein B₁₀₀ (apo B₁₀₀) of coronary heart disease group are significantly different from the control group ( P< 0.05). Plasma ASP correlated positively with BMI, TC, triglyceride, LDL and apo B₁₀₀ (respectively r = 0.42, P< 0.01; r = 0.36, p<0.01; r = 0.20, p<0.05; r = 0.31, p<0.05; r = 0.45, p<0.01). Conclusion Plasma ASP takes part in the generation of the disorder of lipid metabolism in coronary heart disease. ASP could be used as a new indicator to evaluate the risk to develop cardiovascular disease.